144 related articles for article (PubMed ID: 25400774)
1. T-box transcription factor 21 expression in breast cancer and its relationship with prognosis.
Yu H; Yang J; Jiao S; Li Y; Zhang W; Wang J
Int J Clin Exp Pathol; 2014; 7(10):6906-13. PubMed ID: 25400774
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of B lymphocytes in invasive carcinoma of the breast.
Mahmoud SM; Lee AH; Paish EC; Macmillan RD; Ellis IO; Green AR
Breast Cancer Res Treat; 2012 Apr; 132(2):545-53. PubMed ID: 21671016
[TBL] [Abstract][Full Text] [Related]
3. TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer.
Yu HM; Yang JL; Jiao SC; Wang JD; Li Y
J Huazhong Univ Sci Technolog Med Sci; 2014 Feb; 34(1):51-58. PubMed ID: 24496679
[TBL] [Abstract][Full Text] [Related]
4. T-bet
Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
[TBL] [Abstract][Full Text] [Related]
5. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
Lee M; Tayyari F; Pinnaduwage D; Bayani J; Bartlett JMS; Mulligan AM; Bull SB; Andrulis IL
BMC Cancer; 2018 Jul; 18(1):750. PubMed ID: 30029633
[TBL] [Abstract][Full Text] [Related]
6. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
7. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.
Cao L; Sun PL; Yao M; Jia M; Gao H
Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis.
Yu H; Yang J; Jiao S; Li Y; Zhang W; Wang J
Cancer Immunol Immunother; 2015 Jul; 64(7):853-60. PubMed ID: 25893809
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
[TBL] [Abstract][Full Text] [Related]
10. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.
Alford SH; Toy K; Merajver SD; Kleer CG
Breast Cancer Res Treat; 2012 Apr; 132(2):429-37. PubMed ID: 21614565
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression.
Stenström J; Hedenfalk I; Hagerling C
Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289
[TBL] [Abstract][Full Text] [Related]
13. Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor.
Allard MA; Bachet JB; Beauchet A; Julie C; Malafosse R; Penna C; Nordlinger B; Emile JF
Diagn Pathol; 2012 Nov; 7():156. PubMed ID: 23148481
[TBL] [Abstract][Full Text] [Related]
14. Higher Numbers of T-Bet+ Tumor-Infiltrating Lymphocytes Associate with Better Survival in Human Epithelial Ovarian Cancer.
Xu Y; Chen L; Xu B; Xiong Y; Yang M; Rui X; Shi L; Wu C; Jiang J; Lu B
Cell Physiol Biochem; 2017; 41(2):475-483. PubMed ID: 28214872
[TBL] [Abstract][Full Text] [Related]
15. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
[TBL] [Abstract][Full Text] [Related]
16. The Role of CXCL13 and CXCL9 in Early Breast Cancer.
Razis E; Kalogeras KT; Kotsantis I; Koliou GA; Manousou K; Wirtz R; Veltrup E; Patsea H; Poulakaki N; Dionysopoulos D; Pervana S; Gogas H; Koutras A; Pentheroudakis G; Christodoulou C; Linardou H; Pavlakis K; Koletsa T; Pectasides D; Zagouri F; Fountzilas G
Clin Breast Cancer; 2020 Feb; 20(1):e36-e53. PubMed ID: 31699671
[TBL] [Abstract][Full Text] [Related]
17. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
19. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
[TBL] [Abstract][Full Text] [Related]
20. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
